Hemosiderosis secondary prevention

	Hemosiderosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hemosiderosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hemosiderosis secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hemosiderosis secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hemosiderosis secondary prevention
CDC on Hemosiderosis secondary prevention
Hemosiderosis secondary prevention in the news
Blogs on Hemosiderosis secondary prevention
Directions to Hospitals Treating Hemosiderosis
Risk calculators and risk factors for Hemosiderosis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Preventive measures for the secondary prevention of IPH include: maintenance doses of prednisone or prednisolone of 10 to 15 mg/kg/day

Preventive measures for the secondary prevention of IPH include:

In general, if the patient does not have any recurrence in 18 to 24 months, further tapering and discontinuation of steroids can be attempted.^[1]

↑ Yang CT, Chiang BL, Wang LC (June 2020). "Aggressive corticosteroid treatment in childhood idiopathic pulmonary hemosiderosis with better outcome". J. Formos. Med. Assoc. doi:10.1016/j.jfma.2020.05.022. PMID 32505591 Check |pmid= value (help).